Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRMG vs ACET: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACET Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

ACET Overall Winner 6-Pillar Tally: CRMG 1 – 4 ACET (1 Tie) Matrix Metrics: CRMG 2 – 6 ACET

As of Nov 16, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Leverage Shares 2X Long CRM Daily ETF (CRMG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMG carries a Unified Composite Score of 63.5/100 (BUY) at $6.66 (N/M Forward P/E, N/A operating margin), whereas ACET carries 43.8/100 (HOLD) at $2.64 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CRMG currently prints a higher short-term Unified Composite Score (63.5/100 BUY vs. ACET 43.8/100 HOLD), ACET captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: CRMG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile ACET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 16.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMG vs ACET
CRMG NASDAQ
Leverage Shares 2X Long CRM Daily ETF
Institutional Equity
$6.66
-2.2% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 61% Vol
Unified Composite Score
63.5 / 100 BUY
Tech 75.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $7.64 · SMA50: $8.15
ACET NASDAQ Head-to-Head Winner
Adicet Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.64
-5.04% 1D
Market Cap $27.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 45% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 25.0 Fund 58.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.5%), weak momentum, RSI 16
RSI-14: 16.5 · SMA20: $3.43 · SMA50: $5.79

6-Pillar Scorecard Institutional Category Breakdown (CRMG 1 – 4 ACET)

Columns: Metric · CRMG · ACET
1. Valuation Multiples ACET
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M 0.82x
EV / Revenue N/M N/M
2. Growth & Scale ACET
Revenue Growth (YoY) N/A -100.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $27.4M
3. Profitability & Quality ACET
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -78.1%
4. Balance Sheet & Cash Flow ACET
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $15M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRMG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 107.3% (39th %ile) 84.5% (6th %ile)
Put/Call OI Skew N/A 1.22x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMG (2) vs ACET (6)
Institutional Metric CRMG ACET Criterion Row Edge
Market Capitalization
Scale
N/A $27.4M Larger Scale ACET
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -100.0% Higher Growth ACET
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ACET
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ACET
Return on Equity (ROE)
Capital Efficiency
N/A -78.1% Higher ROE ACET
52-Week Range Position
Momentum
29% ($4–$14) 23% ($0–$10) Stronger Trend CRMG
Beta / 30D Volatility
Risk Regime
0.46β · 61% Vol 1.91β · 45% Vol Lower Realized Risk ACET
Unified Institutional Score
Composite Signal
63.5 / 100 (BUY) 43.8 / 100 (HOLD) Higher Composite CRMG
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.82x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($15M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRMG +20.4 pp
CRMG: -21.83% · ACET: -42.23%
3M Horizon CRMG +80.2 pp
CRMG: +9.18% · ACET: -71.02%
6M Horizon CRMG +83.94 pp
CRMG: +19.14% · ACET: -64.8%
1Y Horizon ACET +340.47 pp
CRMG: -42.34% · ACET: +298.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMG vs ACET. Trailing 12-month operating profitability (CRMG N/A vs ACET 0.0%) and valuation multiples (CRMG N/M vs ACET N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRMG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ACET ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-78.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 107.3%
IV Percentile 39th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRMG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACET BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 6th %ile
Put/Call OI Skew 1.22x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACET Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACET Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $27.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMG vs ACET Key Questions & Quantitative Answers

As of Nov 16, 2026, Adicet Bio, Inc. (ACET) is the stronger overall head-to-head candidate over Leverage Shares 2X Long CRM Daily ETF (CRMG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMG carries a Unified Composite Score of 63.5/100 (BUY) at $6.66 (N/M Forward P/E, N/A operating margin), whereas ACET carries 43.8/100 (HOLD) at $2.64 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CRMG currently prints a higher short-term Unified Composite Score (63.5/100 BUY vs. ACET 43.8/100 HOLD), ACET captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY). Technical & Structure Timing Caution: CRMG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8); meanwhile ACET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 16.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACET leads the Growth & Scale pillar: CRMG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACET at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMG generates N/A in USD-normalized revenue versus N/A for ACET. In operating R&D and SG&A reinvestment, CRMG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACET.

ACET screens cheaper on headline valuation multiples. CRMG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACET trades at N/M Forward P/E, N/M Trailing P/E, 0.82x PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMG (N/A ROE) versus ACET (-78.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMG carries 107.3% implied volatility (39th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 61% Vol realized risk). By comparison, ACET carries 84.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 1.22x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.91β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.